Benzinga··Vandana SinghPfizer's Braftovi Combination Therapy Receives Full FDA Approval for BRAF-Mutated Colorectal Cancer
Pfizer's Braftovi receives full FDA approval for treating BRAF-mutated metastatic colorectal cancer when combined with cetuximab and chemotherapy, based on Phase 3 trial data.
PFEFDA approvalPhase 3 trial